Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: Implications for rapid susceptibility testing

Amy S. Piatek, Amalio Telenti, Megan R. Murray, Hiyam El-Hajj, William R. Jacobs, Fred Russell Kramer, David Alland

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Past genotypic studies of Mycobacterium tuberculosis may have incorrectly estimated the importance of specific drug resistance mutations due to a number of sampling biases including an overrepresentation of multidrug-resistant (MDR) isolates. An accurate assessment of resistance mutations is crucial for understanding basic resistance mechanisms and designing genotypic drug resistance assays. We developed a rapid closed-tube PCR assay using fluorogenic reporter molecules called molecular beacons to detect reportedly common M. tuberculosis mutations associated with resistance to isoniazid and rifampin. The assay was used in a comparative genotypic investigation of two different study populations to determine whether these known mutations account for most cases of clinical drug resistance. We analyzed samples from a reference laboratory in Madrid, Spain, which receives an overrepresentation of MDR isolates similar to prior studies and from a community medical center in New York where almost all of the resistant isolates and an equal number of susceptible controls were available. The ability of the molecular beacon assay to predict resistance to isoniazid and rifampin was also assessed. The overall sensitivity and specificity of the assay for isoniazid resistance were 85 and 100%, respectively, and those for rifampin resistance were 98 and 100%, respectively. Rifampin resistance mutations were detected equally well in isolates from both study populations; however, isoniazid resistance mutations were detected in 94% of the isolates from Madrid but in only 76% of the isolates from New York (P = 0.02). In New York, isoniazid resistance mutations were significantly more common in the MDR isolates (94%) than in single-drug-resistant isolates (44%; P < 0.001). No association between previously described mutations in the kasA gene and isoniazid resistance was found. The first mutations that cause isoniazid resistance may often occur in sequences that have not been commonly associated with isoniazid resistance, possibly in other as yet uncharacterized genes. The molecular beacon assay was simple, rapid, and highly sensitive for the detection of rifampin-resistant M. tuberculosis isolates and for the detection of isoniazid resistance in MDR isolates.

Original languageEnglish (US)
Pages (from-to)103-110
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume44
Issue number1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Isoniazid
Mycobacterium tuberculosis
Mutation
Rifampin
Population
Drug Resistance
Selection Bias
Multiple Drug Resistance
Spain
Genes
Sensitivity and Specificity
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons : Implications for rapid susceptibility testing. / Piatek, Amy S.; Telenti, Amalio; Murray, Megan R.; El-Hajj, Hiyam; Jacobs, William R.; Kramer, Fred Russell; Alland, David.

In: Antimicrobial Agents and Chemotherapy, Vol. 44, No. 1, 01.01.2000, p. 103-110.

Research output: Contribution to journalArticle

Piatek, Amy S. ; Telenti, Amalio ; Murray, Megan R. ; El-Hajj, Hiyam ; Jacobs, William R. ; Kramer, Fred Russell ; Alland, David. / Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons : Implications for rapid susceptibility testing. In: Antimicrobial Agents and Chemotherapy. 2000 ; Vol. 44, No. 1. pp. 103-110.
@article{929e8d50127247eaaf6dc9c63e6e2cb4,
title = "Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: Implications for rapid susceptibility testing",
abstract = "Past genotypic studies of Mycobacterium tuberculosis may have incorrectly estimated the importance of specific drug resistance mutations due to a number of sampling biases including an overrepresentation of multidrug-resistant (MDR) isolates. An accurate assessment of resistance mutations is crucial for understanding basic resistance mechanisms and designing genotypic drug resistance assays. We developed a rapid closed-tube PCR assay using fluorogenic reporter molecules called molecular beacons to detect reportedly common M. tuberculosis mutations associated with resistance to isoniazid and rifampin. The assay was used in a comparative genotypic investigation of two different study populations to determine whether these known mutations account for most cases of clinical drug resistance. We analyzed samples from a reference laboratory in Madrid, Spain, which receives an overrepresentation of MDR isolates similar to prior studies and from a community medical center in New York where almost all of the resistant isolates and an equal number of susceptible controls were available. The ability of the molecular beacon assay to predict resistance to isoniazid and rifampin was also assessed. The overall sensitivity and specificity of the assay for isoniazid resistance were 85 and 100{\%}, respectively, and those for rifampin resistance were 98 and 100{\%}, respectively. Rifampin resistance mutations were detected equally well in isolates from both study populations; however, isoniazid resistance mutations were detected in 94{\%} of the isolates from Madrid but in only 76{\%} of the isolates from New York (P = 0.02). In New York, isoniazid resistance mutations were significantly more common in the MDR isolates (94{\%}) than in single-drug-resistant isolates (44{\%}; P < 0.001). No association between previously described mutations in the kasA gene and isoniazid resistance was found. The first mutations that cause isoniazid resistance may often occur in sequences that have not been commonly associated with isoniazid resistance, possibly in other as yet uncharacterized genes. The molecular beacon assay was simple, rapid, and highly sensitive for the detection of rifampin-resistant M. tuberculosis isolates and for the detection of isoniazid resistance in MDR isolates.",
author = "Piatek, {Amy S.} and Amalio Telenti and Murray, {Megan R.} and Hiyam El-Hajj and Jacobs, {William R.} and Kramer, {Fred Russell} and David Alland",
year = "2000",
month = "1",
day = "1",
doi = "10.1128/AAC.44.1.103-110.2000",
language = "English (US)",
volume = "44",
pages = "103--110",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons

T2 - Implications for rapid susceptibility testing

AU - Piatek, Amy S.

AU - Telenti, Amalio

AU - Murray, Megan R.

AU - El-Hajj, Hiyam

AU - Jacobs, William R.

AU - Kramer, Fred Russell

AU - Alland, David

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Past genotypic studies of Mycobacterium tuberculosis may have incorrectly estimated the importance of specific drug resistance mutations due to a number of sampling biases including an overrepresentation of multidrug-resistant (MDR) isolates. An accurate assessment of resistance mutations is crucial for understanding basic resistance mechanisms and designing genotypic drug resistance assays. We developed a rapid closed-tube PCR assay using fluorogenic reporter molecules called molecular beacons to detect reportedly common M. tuberculosis mutations associated with resistance to isoniazid and rifampin. The assay was used in a comparative genotypic investigation of two different study populations to determine whether these known mutations account for most cases of clinical drug resistance. We analyzed samples from a reference laboratory in Madrid, Spain, which receives an overrepresentation of MDR isolates similar to prior studies and from a community medical center in New York where almost all of the resistant isolates and an equal number of susceptible controls were available. The ability of the molecular beacon assay to predict resistance to isoniazid and rifampin was also assessed. The overall sensitivity and specificity of the assay for isoniazid resistance were 85 and 100%, respectively, and those for rifampin resistance were 98 and 100%, respectively. Rifampin resistance mutations were detected equally well in isolates from both study populations; however, isoniazid resistance mutations were detected in 94% of the isolates from Madrid but in only 76% of the isolates from New York (P = 0.02). In New York, isoniazid resistance mutations were significantly more common in the MDR isolates (94%) than in single-drug-resistant isolates (44%; P < 0.001). No association between previously described mutations in the kasA gene and isoniazid resistance was found. The first mutations that cause isoniazid resistance may often occur in sequences that have not been commonly associated with isoniazid resistance, possibly in other as yet uncharacterized genes. The molecular beacon assay was simple, rapid, and highly sensitive for the detection of rifampin-resistant M. tuberculosis isolates and for the detection of isoniazid resistance in MDR isolates.

AB - Past genotypic studies of Mycobacterium tuberculosis may have incorrectly estimated the importance of specific drug resistance mutations due to a number of sampling biases including an overrepresentation of multidrug-resistant (MDR) isolates. An accurate assessment of resistance mutations is crucial for understanding basic resistance mechanisms and designing genotypic drug resistance assays. We developed a rapid closed-tube PCR assay using fluorogenic reporter molecules called molecular beacons to detect reportedly common M. tuberculosis mutations associated with resistance to isoniazid and rifampin. The assay was used in a comparative genotypic investigation of two different study populations to determine whether these known mutations account for most cases of clinical drug resistance. We analyzed samples from a reference laboratory in Madrid, Spain, which receives an overrepresentation of MDR isolates similar to prior studies and from a community medical center in New York where almost all of the resistant isolates and an equal number of susceptible controls were available. The ability of the molecular beacon assay to predict resistance to isoniazid and rifampin was also assessed. The overall sensitivity and specificity of the assay for isoniazid resistance were 85 and 100%, respectively, and those for rifampin resistance were 98 and 100%, respectively. Rifampin resistance mutations were detected equally well in isolates from both study populations; however, isoniazid resistance mutations were detected in 94% of the isolates from Madrid but in only 76% of the isolates from New York (P = 0.02). In New York, isoniazid resistance mutations were significantly more common in the MDR isolates (94%) than in single-drug-resistant isolates (44%; P < 0.001). No association between previously described mutations in the kasA gene and isoniazid resistance was found. The first mutations that cause isoniazid resistance may often occur in sequences that have not been commonly associated with isoniazid resistance, possibly in other as yet uncharacterized genes. The molecular beacon assay was simple, rapid, and highly sensitive for the detection of rifampin-resistant M. tuberculosis isolates and for the detection of isoniazid resistance in MDR isolates.

UR - http://www.scopus.com/inward/record.url?scp=0033989548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033989548&partnerID=8YFLogxK

U2 - 10.1128/AAC.44.1.103-110.2000

DO - 10.1128/AAC.44.1.103-110.2000

M3 - Article

C2 - 10602730

AN - SCOPUS:0033989548

VL - 44

SP - 103

EP - 110

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -